iX Biopharma Ltd. (SG:42C) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
iX Biopharma Ltd. reports promising results from their SEISMIC-CBD study, indicating that their novel CBD sublingual wafer, designed with their proprietary WaferiX technology, is safe and tolerable for kidney failure patients, showing potential to improve multiple debilitating symptoms. The study, a significant first in this patient group, also found meaningful improvements in sleep quality, restless legs syndrome, anorexia, pain, and anxiety. Despite some reported mild adverse effects, the majority of participants experienced symptom relief and some continued using the wafers beyond the study.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.
